» Articles » PMID: 20100957

Impact of Ethnicity on Primary Treatment Choice and Mortality in Men with Prostate Cancer: Data from CaPSURE

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2010 Jan 27
PMID 20100957
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

PURPOSE Men diagnosed with prostate cancer have multiple options available for treatment. Previous reports have indicated a trend of differing modalities of treatment chosen by African American and white men. We investigated the role of ethnicity in primary treatment choice and how this affected overall and cancer-specific mortality. METHODS By utilizing data abstracted from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), patients were compared by ethnicity, primary treatment, number of comorbidities, risk level according to modified D'Amico criteria, age, highest educational level attained, type of insurance, treatment facility, and perception of general health. Multinomial logistic regression analysis was performed to determine the effect of the tested variables on primary treatment and mortality. Results African American men were more likely to receive nonsurgical therapy than white men with equivalent disease characteristics. Whites were 48% less likely than African Americans to receive androgen deprivation therapy (ADT) compared with surgery (P = .02) and were 25% less likely than African Americans to receive radiation therapy compared with surgery (P = .08). Whites with low-risk disease were 71% less likely to receive ADT than African American men with similar disease (P = .01). Adjusted overall and prostate cancer-specific mortality were not significantly different between whites and African Americans (hazard ratios, 0.73 and 0.37, respectively). Risk level, type of treatment, and type of insurance had the strongest effects on risk of mortality. CONCLUSION There is a statistically significant difference in primary treatment for prostate cancer between African American and white men with similar risk profiles. Additional research on the influence of patient/physician education and perception and the role that socioeconomic factors play in mortality from prostate cancer may be areas of focus for public health initiatives.

Citing Articles

Pattern, Clinical Characteristics, and Impact of Family History on Prostate-Specific Antigen in Prostate Cancer: A Multicenter Study.

Iheanacho C, Odili V, Enakirerhi G, Isiwele E, Essiet A Am J Mens Health. 2024; 18(4):15579883241264949.

PMID: 39054776 PMC: 11282506. DOI: 10.1177/15579883241264949.


A comparative study of spinal cord compression management in metastatic prostate cancer: Teaching versus non-teaching hospitals in the United States.

Yazdanpanah O, Mahadevan A, Sharma A, Benjamin D, Kalebasty A Cancer Med. 2023; 13(1):e6845.

PMID: 38146897 PMC: 10807570. DOI: 10.1002/cam4.6845.


The Brazilian national prospective active surveillance (AS) cohort of patients with low-risk prostate cancer in the public health system: vigiaSUS study protocol.

Basso J, de Lima J, Bessel M, Tobar Leitao S, Machado Baptista T, Roithmann S BMC Urol. 2023; 23(1):208.

PMID: 38082337 PMC: 10714582. DOI: 10.1186/s12894-023-01380-w.


Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.

Hwang C, Henderson N, Chu S, Holland B, Cackowski F, Pilling A JAMA Netw Open. 2023; 6(9):e2334208.

PMID: 37721753 PMC: 10507489. DOI: 10.1001/jamanetworkopen.2023.34208.


Racial/ethnic disparities in the distribution and effect of type and number of high-risk criteria on mortality in prostate cancer patients treated with radiotherapy.

Chierigo F, Flammia R, Sorce G, Hoeh B, Hohenhorst L, Panunzio A Arab J Urol. 2023; 21(3):135-141.

PMID: 37521449 PMC: 10373609. DOI: 10.1080/2090598X.2022.2148867.


References
1.
Kawakami J, Cowan J, Elkin E, Latini D, DuChane J, Carroll P . Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer. 2006; 106(8):1708-14. DOI: 10.1002/cncr.21799. View

2.
Hoffman R, Harlan L, Klabunde C, Gilliland F, Stephenson R, Hunt W . Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study. J Gen Intern Med. 2003; 18(10):845-53. PMC: 1494937. DOI: 10.1046/j.1525-1497.2003.21105.x. View

3.
Powell I . Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol. 2007; 177(2):444-9. DOI: 10.1016/j.juro.2006.09.024. View

4.
Schwandt A, Garcia J . Complications of androgen deprivation therapy in prostate cancer. Curr Opin Urol. 2009; 19(3):322-6. DOI: 10.1097/MOU.0b013e32832a082c. View

5.
Hu J, Kwan L, Krupski T, Anger J, Maliski S, Connor S . Determinants of treatment regret in low-income, uninsured men with prostate cancer. Urology. 2008; 72(6):1274-9. DOI: 10.1016/j.urology.2007.11.066. View